Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
5Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Lipella Pharmaceuticals Inc. (LIPO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
9Total relationships
2Distinct source URLs
3High confidence
0.752Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Chemistry, Manufacturing and Controls (“CMC”) section of the IND application prior to and in conjunction with use in any subsequent clinical trial. Our Analytical Laboratory, Equipment & Supplies Our…
Reciprocal relationship from ORANY graph: Reciprocal relationship from LIPO graph: Chemistry, Manufacturing and Controls (“CMC”) section of the IND application prior to and in conjunction with use in…
Lipella Pharmaceuticals Inc. Customers
Ticker
Name
Confidence
Evidence
BRIDGEWAY-DEVELOPMENT-CORPORATION
BRIDGEWAY-DEVELOPMENT-CORPORATION
85%
), commencing August 1, 2023 and co-terminating with the existing Lease on June 30, 2025. Subsequently effective January 1, 2024, the Company terminated the Fourth Floor Lease early at no penalty upo…
Reciprocal relationship from ORANY graph: Reciprocal relationship from LIPO graph: Item 13. Certain Relationships and Related Transactions, and Director Independence 83 Item 14. Principal Accountant …
Item 13. Certain Relationships and Related Transactions, and Director Independence 83 Item 14. Principal Accountant Fees and Services 84 PART IV 86 Item 15. Exhibits and Financial Statement Schedules…
EMERGING-GROWTH-COMPANY
EMERGING-GROWTH-COMPANY
62%
000. General and Administrative Expenses General and administrative expenses were $1,668,757 for the nine months ended September 30, 2025, compared to $1,441,089 for the nine months ended September 3…
OTC-MARKETS-GROUP-INC
OTC-MARKETS-GROUP-INC
62%
), commencing August 1, 2023 and co-terminating with the existing Lease on June 30, 2025. Subsequently effective January 1, 2024, the Company terminated the Fourth Floor Lease early at no penalty upo…
Lipella Pharmaceuticals Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
LIPO-DEBT
Debt stack $264,083
90%
Market cache reports total debt of $264,083.
LIPO-DEBT-10718
Warrants outstanding: 117750
90%
xbrl warrant detail from xbrl 2025-09-30.
Lipella Pharmaceuticals Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Lipella Pharmaceuticals Inc..
Lipella Pharmaceuticals Inc. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for Lipella Pharmaceuticals Inc..
Lipella Pharmaceuticals Inc. Extended Supply Chain Network
